For healthy adults over 70, taking a daily low-dose aspirin does not appear to change the risk of heart attacks or serious bleeding differently depending on whether they have a specific blood cell mutation called CHIP.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of RCTs with CHIP stratification could determine whether aspirin’s net benefit or harm differs consistently across populations with and without CHIP.
A systematic review and meta-analysis of all published RCTs with pre-specified CHIP subgroup analysis, including at least 5 trials with >1,000 participants each, using standardized CHIP detection (VAF ≥2%) and adjudicated outcomes (MACE, bleeding). Primary outcome: interaction p-value for aspirin effect by CHIP status.
An RCT could definitively test whether aspirin’s effect on bleeding or CVD differs in CHIP carriers by randomizing them to aspirin or placebo within CHIP strata.
A multicenter, double-blind RCT of 3,000 adults aged 70+ with confirmed CHIP (VAF ≥5%), randomized 1:1 to 100 mg aspirin or placebo for 5 years, with primary endpoint: composite of MACE or major bleeding. Secondary: all-cause mortality and bleeding severity by VAF tier.
A prospective cohort could assess whether aspirin use modifies the bleeding risk associated with CHIP over time in real-world settings.
A prospective cohort of 10,000 adults aged 70+ with baseline CHIP status (VAF ≥2%) and aspirin use recorded at baseline and annually, followed for 7 years with blinded adjudication of MACE and bleeding events, adjusting for comorbidities and concomitant medications.
A case-control study could compare aspirin exposure in individuals with and without bleeding, stratified by CHIP status, to estimate interaction effects.
A matched case-control study of 800 adults aged 70+ with adjudicated major bleeding (cases) and 1,600 controls without bleeding, stratified by CHIP status (positive/negative), with detailed history of aspirin use (dose, duration, timing) and adjustment for indication bias.
A cross-sectional study could estimate the prevalence of aspirin use among those with CHIP and bleeding, but cannot determine temporal relationships.
A single-timepoint survey of 5,000 adults aged 70+ with known CHIP status and recent bleeding history, measuring current aspirin use and correlating it with bleeding severity and VAF level.